Description: Adicet Bio, Inc., a clinical stage biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for autoimmune diseases and cancer. The company offers gamma delta T cells engineered with chimeric antigen receptors (CARs) to facilitate durable activity in patients. Its lead product candidate is ADI-001, an allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, which is in Phase I clinical trial for the treatment of autoimmune diseases and relapsed or refractory aggressive B cell non-Hodgkin's lymphoma. The company is also developing ADI-270, an armored gamma delta CAR T cell product candidate targeting renal cell carcinoma for treating other CD70+ solid tumor and hematological malignancies indications. The company was founded in 2014 and is based in Boston, Massachusetts.
Home Page: www.adicetbio.com
131 Dartmouth Street
Boston,
MA
02116
United States
Phone:
650 503 9095
Officers
Name | Title |
---|---|
Mr. Chen Schor BA, CPA, M.B.A. | CEO, President & Director |
Dr. Aya Jakobovits Ph.D. | Founder & Independent Director |
Mr. Brian Nicholas Harvey | Chief Financial Officer |
Dr. Donald Healey Ph.D. | Chief Technology Officer |
Dr. Blake Aftab Ph.D. | Senior VP & Chief Scientific Officer |
Ms. Amy Locke | Chief Human Resource Officer |
Dr. Francesco Galimi M.D., Ph.D. | Chief Medical Officer & Senior VP |
Dr. Nancy L. Boman M.D., Ph.D. | Senior VP & Chief Regulatory Officer |
Exchange: F
Country: DE : Germany
Currency: Euro (€)
GIC Sector: | Health Care |
---|---|
GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
GIC Industry: | Biotechnology |
GIC Sub-Industry: | Biotechnology |
Forward PE: | 0 |
---|---|
Trailing PE: | 0 |
Price-to-Book MRQ: | 0.3581 |
Price-to-Sales TTM: | 9.6888 |
IPO Date: | |
Fiscal Year End: | December |
Full Time Employees: | 143 |